nonalcoholic fatty liver disease

nonalcoholic fatty liver disease
Name	Nonalcoholic fatty liver disease
Field	Hepatology
Causes	Metabolic syndrome
Risks	Obesity
Diagnosis	Imaging, biopsy
Treatment	Lifestyle changes, pharmacotherapy

nonalcoholic fatty liver disease is a spectrum of liver disorders characterized by excessive hepatic steatosis in the absence of significant alcohol consumption. Initially recognized in clinical reports from United States hepatology centers and discussed at meetings of the American Association for the Study of Liver Diseases, it has become a global public health concern linked to rising prevalence of Obesity and Type 2 diabetes mellitus. International organizations including the World Health Organization and the Centers for Disease Control and Prevention have highlighted its association with metabolic comorbidities and cardiovascular outcomes.

Signs and symptoms

Patients often present with nonspecific complaints recorded in clinical cohorts from the Mayo Clinic, Cleveland Clinic, and tertiary centers in Johns Hopkins Hospital, including fatigue, malaise, and right upper quadrant discomfort. Physical examination may reveal hepatomegaly noted in case series from Massachusetts General Hospital and community studies in United Kingdom primary care networks such as NHS England. Many individuals are asymptomatic and are identified during routine surveillance programs run by institutions like the American Diabetes Association and screening initiatives at the National Institutes of Health.

Causes and risk factors

Epidemiologic analyses from the Framingham Heart Study, the UK Biobank, and cohorts in Japan implicate insulin resistance syndromes and adiposity as principal drivers. Established risk factors include central obesity described in guidelines by the International Diabetes Federation, dyslipidemia characterized in reports from European Society of Cardiology, and hyperglycemia defined by diagnostic criteria of the American Diabetes Association. Additional contributors identified in population-based studies from Australia, Canada, and China include metabolic syndrome components codified by the National Cholesterol Education Program and genetic susceptibility loci reported by consortia such as the Human Genome Project and genome-wide association studies published in journals affiliated with Nature and The Lancet.

Pathophysiology

Pathogenic models synthesized at conferences of the American Association for the Study of Liver Diseases and summarized in reviews in Gastroenterology propose multi-hit mechanisms involving steatosis, lipotoxicity, oxidative stress, and inflammatory signaling. Experimental work from laboratories at Harvard University, Stanford University, and the Broad Institute details hepatocellular lipid accumulation, mitochondrial dysfunction, and activation of innate immune pathways including inflammasome components studied in research from the Howard Hughes Medical Institute. Fibrogenesis pathways implicate stellate cell activation characterized in translational studies at the Salk Institute and molecular signaling reported in articles associated with the Max Planck Society.

Diagnosis

Diagnostic algorithms endorsed by panels convened by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver employ serum biomarkers, imaging, and histology. Noninvasive tests developed at centers like Mayo Clinic and validated in cohorts from the Framingham Heart Study include liver enzyme panels, the fibrosis-4 index referenced in clinical practice statements from the National Institute for Health and Care Excellence, and elastography techniques commercialized by companies collaborating with GE Healthcare and evaluated in trials registered with the Food and Drug Administration. Liver biopsy remains the reference standard described in textbooks published by Oxford University Press and used in landmark studies from Karolinska Institutet.

Management and treatment

Evidence-based management strategies endorsed by the American Association for the Study of Liver Diseases, the European Association for the Study of the Liver, and the World Gastroenterology Organisation center on weight reduction, glycemic control, and cardiovascular risk mitigation. Lifestyle interventions modeled on trials from Diabetes Prevention Program and implemented in programs at the Mayo Clinic emphasize dietary modification and increased physical activity promoted by organizations such as the American Heart Association. Pharmacotherapies under investigation in randomized trials published in The New England Journal of Medicine and sponsored by academic consortia from University of California, San Francisco include insulin sensitizers, lipid-lowering agents assessed by the European Medicines Agency, and experimental antifibrotic compounds developed with collaboration from the Bill & Melinda Gates Foundation and biotech firms. Bariatric surgery outcomes reported by the American Society for Metabolic and Bariatric Surgery show histologic improvement in selected patients.

Prognosis and complications

Longitudinal cohort studies from the Framingham Heart Study, registries maintained by the European Liver Transplant Registry, and analyses by the United Network for Organ Sharing document progression from simple steatosis to nonalcoholic steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma described in case series from Memorial Sloan Kettering Cancer Center. Cardiovascular disease remains the leading cause of mortality as highlighted in reports by the World Health Organization and the Centers for Disease Control and Prevention, and end-stage liver disease can culminate in liver transplantation coordinated through networks like UNOS and specialized centers such as Addenbrooke's Hospital.

Category:Hepatology